Filing Analysis
The company filed an 8-K to disclose a letter from the CEO to shareholders regarding 'recent development concerning the Company and its business.' The filing is under Item 7.01 (Regulation FD Disclosure) and does not specify the nature of the news in the main text.
🚩 Red Flags
- Vague disclosure: The filing mentions 'recent development' without specifying if it relates to financial distress, legal issues, or operational changes.
- Item 7.01 usage: While often used for non-binding news, in micro-caps, sudden CEO letters regarding 'developments' can precede significant volatility or negative news.
📋 Key Facts
- Filing date: October 24, 2025
- The report contains a CEO letter to shareholders as Exhibit 1.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure).
- The company operates under the DBA SkyTech Orion Global Corp.
Citrine Global, Corp. announced the appointment of Lior Asher to its Board of Directors on October 5, 2025. Mr. Asher brings extensive experience in high-tech investments and holds various leadership roles in Israeli industrial and technology sectors.
🚩 Red Flags
- Potential related-party connection: The new director is a director of the company's wholly owned subsidiary (Citrine Global Israel) which holds a significant stake in SkyTech Orion Ltd.
📋 Key Facts
- Lior Asher appointed as a Director on October 5, 2025.
- Asher is a director of Skytech Orion Israel and Citrine Global Israel (a wholly owned subsidiary).
- Citrine Global Israel holds a 69.5% ownership interest in SkyTech Orion Ltd.
- Asher is the owner/director of Or HaTzvi Group, an industrial conglomerate serving commercial and defense sectors.
- Asher has advisory roles with Citrine SAL Investment Ltd., iBOT Israel Botanicals Ltd., and G2G Ltd.
Citrine Global, Corp. announced that its subsidiary, Cannovation Center Israel Ltd., has been approved for a government grant of 12.5 million NIS (approximately $3.5 million USD). The funds are designated for the development of 'SkyTech,' a Drone and UAV Operational Innovation Center in Yerucham, Israel.
📋 Key Facts
- Grant amount: 12.5 million NIS (~$3.5 million USD).
- Grant source: Ministry of Economy and Industry (Israel).
- Purpose: Development of SkyTech - a Drone and UAV Operational Innovation Center.
- Location: Land owned by Cannovation in Yerucham, Israel.
- Ownership structure: Citrine Global owns 60% of Cannovation via its subsidiary CTGL – Citrine Global Israel Ltd.
Citrine Global, Corp. entered into a term sheet for a $137,000 equity investment from Deer Light Ltd. and simultaneously converted approximately $1.88 million in debt into common stock and warrants at an extremely low conversion price of $0.01 per share.
🚩 Red Flags
- Extreme dilution: The conversion of $1.88M debt into shares at $0.01 per share will result in massive share issuance, significantly diluting existing shareholders.
- Penny stock pricing: Both the new investment and the debt conversion are occurring at a nominal price of $0.01, indicating severe distress or lack of market value.
- Potential 'Death Spiral' mechanics: The combination of extremely low-priced warrants and massive share issuations is characteristic of predatory financing structures.
- Use of proceeds: The company explicitly stated it intends to use funds to pay for periodic filings, suggesting a lack of operational liquidity.
📋 Key Facts
- Entered into a term sheet with Deer Light Ltd. for $137,000 to purchase units (one share + one warrant) at $0.01 per unit.
- Approximately $120,000 in subscription proceeds have already been received.
- Converted $1,880,000 of principal debt from three Israeli partnerships into common stock and warrants.
- The conversion price for the debt-to-equity swap was set at $0.01 per share.
- Warrants were issued alongside converted shares with an exercise price of $0.01.
- Accrued interest on the original notes remains due when the company raises at least $5 million in gross proceeds.
Citrine Global, Corp. entered into a term sheet with X Group Fund of Funds Limited Partnership for a $250,000 investment in exchange for 25,000,000 units (stock + warrants) at a nominal price of $0.01 per unit. The company intends to use the proceeds primarily to fund required periodic filings.
🚩 Red Flags
- Extremely low share price ($0.01 per unit) indicates a highly distressed or shell-like valuation.
- Massive dilution: 25,000,000 shares for only $250,000 represents an effective price of $0.00001 per share.
- Use of proceeds is specifically to fund 'required periodic filings,' suggesting the company may be in danger of delisting or non-compliance due to missing reports.
- The inclusion of a consulting agreement for 25,000,000 shares suggests significant potential for further dilution and related-party influence.
📋 Key Facts
- Total investment amount: $250,000 via two tranches ($100k by Aug 31, 2024; $150k by Sept 30, 2024).
- Consideration: 25,000,000 units, each consisting of one share of common stock and one warrant to purchase an additional share at $0.01.
- X Group receives the right to recommend two director nominees meeting US Exchange standards upon completion.
- A consulting agreement involving 25,000,000 shares is contemplated subject to investment completion.
- Proceeds are earmarked for preparing and filing required periodic SEC filings.
Citrine Global, Corp. announced the resignation of Director Doron Birger from the Board of Directors, effective February 22, 2024.
📋 Key Facts
- Doron Birger resigned from the Board of Directors on February 22, 2024.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Mr. Birger expressed interest in continuing to work with the Company in an advisory or consulting capacity.
Citrine Global Corp. entered into a $63,250 promissory note with 1800 Diagonal Lending LLC on February 9, 2024. The agreement includes significant debt-to-equity conversion features at a steep discount to market price.
🚩 Red Flags
- Highly dilutive conversion feature (39% discount to lowest price)
- Significant share reserve (over 51 million shares) relative to typical micro-cap structures
- Lender has unilateral right to increase the number of reserved shares
- High default interest rate of 22%
📋 Key Facts
- Principal amount of Note: $63,250
- Gross proceeds received by Company: $55,000 (due to original issue discount)
- Total payback to Lender: $72,737.00 via nine payments of $8,081.89
- Interest rate: 15% per annum; Default interest: 22% per annum
- Maturity date: November 15, 2024
- Conversion feature: Lender can convert debt to common stock at a price equal to 61% of the lowest trading price during the 20 trading days prior to conversion (a 39% discount).
- Shares reserved for potential conversion: Initially 51,844,262 shares.
Citrine Global, Corp. consummated a Share Purchase and Option Agreement to acquire a 19% equity stake in iBOT Israel Botanicals Ltd. for $10 million via the issuance of 70,370,370 shares at $0.027 per share.
🚩 Red Flags
- Massive dilution: Issuance of over 70 million shares at a very low price ($0.027) represents significant dilution for existing shareholders.
- Concentrated Director Compensation: Large grants of restricted shares to directors (e.g., CFO received 14.7M shares) immediately following a major acquisition.
- Potential cash drain: The option to increase iBOT stake to 51% requires the company to fund iBOT's operating budget for 24 months.
📋 Key Facts
- Acquired 19% equity stake in iBOT Israel Botanicals Ltd. on December 31, 2023.
- Consideration: Issuance of 70,370,370 shares of Citrine Global common stock.
- Share price used for calculation: $0.027 per share (based on 30-day high closing price).
- The transaction valuation was based on a discounted pre-company valuation by an independent third party.
- Company holds an option to increase iBOT stake to 51% through June 30, 2024 via shares and cash.
- Includes a 'no-shop' clause for the duration of the option period.
- Board granted restricted shares to directors: Ilanit Halperin (14.7M), David Kretzmer (7.525M), and Doron Birger (916,230).